基于EEG的临床决策支持系统用于使用EMD和深度学习技术诊断阿尔茨海默氏症疾病
Khalil AlSharabi1, Yasser Bin Salamah1, Majid Aljalal1
1Electrical Engineering Department, College of Engineering, King Saud University, Riyadh, Saudi Arabia.
Frontiers in human neuroscience
|September 18, 2023
概括
电脑电图 (EEG) 数据显示了早期阿尔茨海默病 (AD) 检测的前景. 这项研究开发了一个使用EEG信号处理的决策支持系统,在识别轻度和中度AD病例方面实现了高精度.
科学领域:
- 神经科学是一个神经科学.
- 生物医学工程 生物医学工程
- 人工智能的人工智能
背景情况:
- 早期发现阿尔茨海默病 (AD) 对于有效管理至关重要.
- 电脑电图 (EEG) 信号提供了一种有希望的,非侵入性的神经障碍评估方法.
- 现有的临床技术可能并不总是能够在早期阶段识别AD.
研究的目的:
- 开发一个可靠和准确的临床决策支持系统,用于使用EEG早期发现AD.
- 利用EEG信号处理和人工智能来区分神经型个体和轻度至中度AD的个体.
- 为了比较各种AI方法在分析AD诊断的EEG特征方面的有效性.
主要方法:
- 使用了一组数据集,其中包括神经类型个体和轻度和中度AD患者的EEG记录.
- 应用带通波和经验模式分解 (EMD) 进行EEG信号特征提取.
- 采用人工智能分类器,并使用k-fold和leave-one-subject-out (LOSO) 交叉验证来评估性能.
主要成果:
- 通过k倍交叉验证实现了99.9%的最大分类准确度.
- 使用LOSO交叉验证方法实现了94.8%的分类准确度.
- 证明了综合信号特征和人工智能的有效性,用于区分AD严重程度.
结论:
- 拟议的基于EEG的诊断支持系统显示了早期AD检测的巨大潜力.
- 研究结果表明,开发的方法可以帮助识别AD的新型诊断生物标志物.
- 这种方法为阿尔茨海默病的早期临床诊断提供了一个有希望的补充工具.
更多相关视频
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.6K
11:25Simultaneous Scalp Electroencephalography EEG, Electromyography EMG, and Whole-body Segmental Inertial Recording for Multi-modal Neural Decoding
Published on: July 26, 2013
43.4K
相关概念视频
Alzheimer's Disease: Overview
517
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
517
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
